Jérémie Thereaux1,2,3, Thomas Lesuffleur1, Sébastien Czernichow4,5, Arnaud Basdevant6,7, Simon Msika8, David Nocca9, Bertrand Millat1, Anne Fagot-Campagna1. 1. Department of Statistics, Caisse Nationale d'Assurance Maladie des Travailleurs Salariés, Paris, France. 2. Department of General, Digestive and Metabolic Surgery, La Cavale Blanche University Hospital, Brest, France. 3. University of Bretagne Occidentale, Equipe d'Accueil 3878 Groupe d'Étude de la Thrombose en Bretagne Occidentale (GETBO), Brest, France. 4. Department of Nutrition, Hôpital Européen Georges-Pompidou, Centre Spécialisé Obésité Ile de France Sud, Assistance Publique-Hôpitaux de Paris, Paris, France. 5. The University Paris Descartes, Paris, France. 6. Department of Heart and Nutrition, The Institute of Cardiometabolism and Nutrition, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France. 7. University Pierre et Marie Curie Paris 6, Paris, France. 8. Department of General, Digestive and Metabolic Surgery, Louis Mourier Hospital, Assistance Publique-Hôpitaux de Paris, Diderot University Paris 7, Colombes, France. 9. Department of Surgery, Centre Hospitalier Universitaire Montpellier, Faculty of Medicine of Montpellier, Montpellier, France.
Abstract
Importance: Few large-scale long-term prospective cohort studies have assessed changes in antidiabetes treatment after bariatric surgery. Objective: To describe the association between bariatric surgery and rates of continuation, discontinuation, or initiation of antidiabetes treatment 6 years after bariatric surgery compared with a matched control obese group. Design, Setting, and Participants: This nationwide observational population-based cohort study extracted health care reimbursement data from the French national health insurance database from January 1, 2008, to December 31, 2015. All patients undergoing primary bariatric surgery in France between January 1 and December 31, 2009, were matched on age, sex, body mass index category, and antidiabetes treatment with control patients hospitalized for obesity in 2009 with no bariatric surgery between 2005 and 2015. Exposures: Bariatric surgery, including adjustable gastric banding (AGB), gastric bypass (GBP), and sleeve gastrectomy (SG). Main Outcome and Measure: Reimbursement for antidiabetes drugs. Mixed-effects logistic regression models estimated factors of discontinuation or initiation of antidiabetes treatment over a period of 6 years. Results: In 2009, a total of 15 650 patients (mean [SD] age, 38.9 [11.2] years; 84.6% female; 1633 receiving antidiabetes treatment) underwent primary bariatric surgery, with 48.5% undergoing AGB, 27.7% undergoing GBP, and 22.0% undergoing SG. Among patients receiving antidiabetes treatment at baseline, the antidiabetes treatment discontinuation rate was higher 6 years after bariatric surgery than in controls (-49.9% vs -9.0%, P < .001). In multivariable analysis, the main predictive factors for discontinuation were the following: GBP (odds ratio [OR], 16.7; 95% CI, 13.0-21.4), SG (OR, 7.30; 95% CI, 5.50-9.50), and AGB (OR, 4.30; 95% CI, 3.30-5.60) compared with no bariatric surgery, as well as insulin use (OR, 0.17; 95% CI, 0.13-0.22), dual therapy without insulin (OR, 0.38; 95% CI, 0.32-0.45) vs monotherapy, lipid-lowering treatment (OR, 0.76; 95% CI, 0.63-0.91), antidepressant treatment (OR, 0.67; 95% CI, 0.55-0.81), and age (OR, 0.96; 95% CI, 0.95-0.97) per year. For patients without antidiabetes treatment at baseline, the 6-year antidiabetes treatment initiation rate was much lower after bariatric surgery than in controls (1.4% vs 12.0%, P < .001). In multivariable analysis, protective factors were GBP (OR, 0.06; 95% CI, 0.04-0.09), SG (OR, 0.08; 95% CI, 0.06-0.11), and AGB (OR, 0.16; 95% CI, 0.14-0.20) vs controls, and risk factors were as follows: body mass index category (OR, 2.04; 95% CI, 1.68-2.47 for ≥50.0 vs 30.0-39.9 and OR, 1.68; 95% CI, 1.49-1.90 for 40.0-49.9 vs 30.0-39.9), antihypertensive treatment (OR, 1.49; 95% CI, 1.33-1.67), low income (OR, 1.43; 95 % CI, 1.26-1.62), and age (OR, 1.04; 95 % CI, 1.03-1.05) per year. Conclusions and Relevance: Bariatric surgery was associated with a significantly higher 6-year postoperative antidiabetes treatment discontinuation rate compared with baseline and with an obese control group without bariatric surgery.
Importance: Few large-scale long-term prospective cohort studies have assessed changes in antidiabetes treatment after bariatric surgery. Objective: To describe the association between bariatric surgery and rates of continuation, discontinuation, or initiation of antidiabetes treatment 6 years after bariatric surgery compared with a matched control obese group. Design, Setting, and Participants: This nationwide observational population-based cohort study extracted health care reimbursement data from the French national health insurance database from January 1, 2008, to December 31, 2015. All patients undergoing primary bariatric surgery in France between January 1 and December 31, 2009, were matched on age, sex, body mass index category, and antidiabetes treatment with control patients hospitalized for obesity in 2009 with no bariatric surgery between 2005 and 2015. Exposures: Bariatric surgery, including adjustable gastric banding (AGB), gastric bypass (GBP), and sleeve gastrectomy (SG). Main Outcome and Measure: Reimbursement for antidiabetes drugs. Mixed-effects logistic regression models estimated factors of discontinuation or initiation of antidiabetes treatment over a period of 6 years. Results: In 2009, a total of 15 650 patients (mean [SD] age, 38.9 [11.2] years; 84.6% female; 1633 receiving antidiabetes treatment) underwent primary bariatric surgery, with 48.5% undergoing AGB, 27.7% undergoing GBP, and 22.0% undergoing SG. Among patients receiving antidiabetes treatment at baseline, the antidiabetes treatment discontinuation rate was higher 6 years after bariatric surgery than in controls (-49.9% vs -9.0%, P < .001). In multivariable analysis, the main predictive factors for discontinuation were the following: GBP (odds ratio [OR], 16.7; 95% CI, 13.0-21.4), SG (OR, 7.30; 95% CI, 5.50-9.50), and AGB (OR, 4.30; 95% CI, 3.30-5.60) compared with no bariatric surgery, as well as insulin use (OR, 0.17; 95% CI, 0.13-0.22), dual therapy without insulin (OR, 0.38; 95% CI, 0.32-0.45) vs monotherapy, lipid-lowering treatment (OR, 0.76; 95% CI, 0.63-0.91), antidepressant treatment (OR, 0.67; 95% CI, 0.55-0.81), and age (OR, 0.96; 95% CI, 0.95-0.97) per year. For patients without antidiabetes treatment at baseline, the 6-year antidiabetes treatment initiation rate was much lower after bariatric surgery than in controls (1.4% vs 12.0%, P < .001). In multivariable analysis, protective factors were GBP (OR, 0.06; 95% CI, 0.04-0.09), SG (OR, 0.08; 95% CI, 0.06-0.11), and AGB (OR, 0.16; 95% CI, 0.14-0.20) vs controls, and risk factors were as follows: body mass index category (OR, 2.04; 95% CI, 1.68-2.47 for ≥50.0 vs 30.0-39.9 and OR, 1.68; 95% CI, 1.49-1.90 for 40.0-49.9 vs 30.0-39.9), antihypertensive treatment (OR, 1.49; 95% CI, 1.33-1.67), low income (OR, 1.43; 95 % CI, 1.26-1.62), and age (OR, 1.04; 95 % CI, 1.03-1.05) per year. Conclusions and Relevance: Bariatric surgery was associated with a significantly higher 6-year postoperative antidiabetes treatment discontinuation rate compared with baseline and with an obese control group without bariatric surgery.
Authors: Ida J Hatoum; Robin Blackstone; Tina D Hunter; Diane M Francis; Michael Steinbuch; Jason L Harris; Lee M Kaplan Journal: JAMA Surg Date: 2016-02 Impact factor: 14.766
Authors: Nancy Puzziferri; Thomas B Roshek; Helen G Mayo; Ryan Gallagher; Steven H Belle; Edward H Livingston Journal: JAMA Date: 2014-09-03 Impact factor: 56.272
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Stacy A Brethauer; Sankar D Navaneethan; Ali Aminian; Claire E Pothier; Esther S H Kim; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2014-03-31 Impact factor: 91.245
Authors: John B Dixon; Linda M Schachter; Paul E O'Brien; Kay Jones; Mariee Grima; Gavin Lambert; Wendy Brown; Michael Bailey; Matthew T Naughton Journal: JAMA Date: 2012-09-19 Impact factor: 56.272
Authors: Ted D Adams; Richard E Gress; Sherman C Smith; R Chad Halverson; Steven C Simper; Wayne D Rosamond; Michael J Lamonte; Antoinette M Stroup; Steven C Hunt Journal: N Engl J Med Date: 2007-08-23 Impact factor: 91.245
Authors: Goodarz Danaei; Mariel M Finucane; Yuan Lu; Gitanjali M Singh; Melanie J Cowan; Christopher J Paciorek; John K Lin; Farshad Farzadfar; Young-Ho Khang; Gretchen A Stevens; Mayuree Rao; Mohammed K Ali; Leanne M Riley; Carolyn A Robinson; Majid Ezzati Journal: Lancet Date: 2011-06-24 Impact factor: 79.321
Authors: Jonathan Q Purnell; Faith Selzer; Abdus S Wahed; John Pender; Walter Pories; Alfons Pomp; Greg Dakin; James Mitchell; Luis Garcia; Myrlene A Staten; Carol McCloskey; David E Cummings; David R Flum; Anita Courcoulas; Bruce M Wolfe Journal: Diabetes Care Date: 2016-07 Impact factor: 19.112
Authors: Douglas Barthold; Elizabeth Brouwer; Lee J Barton; David E Arterburn; Anirban Basu; Anita Courcoulas; Cecelia L Crawford; Peter N Fedorka; Heidi Fischer; Benjamin B Kim; Edward C Mun; Sameer B Murali; Kristi Reynolds; Tae K Yoon; Robert E Zane; Karen J Coleman Journal: Diabetes Care Date: 2022-01-01 Impact factor: 17.152